Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

By sjmartinez • February 24, 2023

Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. PMID: 36816342; PMCID: PMC9932343.

Tags: Dermatology, Olive View DoM, Publications

Evaluation and Treatment of Elevated Bile Acids in Chronic Pruritus of the Elderly: A Case Series

Truong A, Schoettinger K, Kaffenberger BH, Milani-Nejad N. Evaluation and Treatment of Elevated Bile Acids in Chronic Pruritus of the Elderly: A Case Series. Int[...]

Artificial Intelligence in Patch Testing: Comprehensive Review of Current Applications and Future Prospects in Dermatology

Tang HS, Ebriani J, Yan MJ, Wongvibulsin S, Farshchian M. Artificial Intelligence in Patch Testing: Comprehensive Review of Current Applications and Future Prospects in Dermatology.[...]

MicroBayesAge: a maximum likelihood approach to predict epigenetic age using microarray data

Nolan N, Mitchell M, Mboning L, Bouchard LS, Pellegrini M. MicroBayesAge: a maximum likelihood approach to predict epigenetic age using microarray data. Geroscience. 2025 May[...]